Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23457529 | 1.00 | HTR3A (0.35) | HTR3AHRH4PDE3BPDE3AHRH3 | |
| SCHEMBL29699478 | 0.81 | LMNA (0.40) | SMN1; SMN2DYRK1AALDH1A1CYP2A6 | |
| SCHEMBL23457595 | 0.81 | LMNA (0.40) | SMN1; SMN2DYRK1AALDH1A1CYP2A6 | |
| SCHEMBL8559109 | 0.71 | HTR3A (0.37) | HTR3AHRH4PDE3BPDE3AHRH3 | |
| SCHEMBL8559644 | 0.71 | MAPT (0.53) | BACE1HPGDSMN1; SMN2PIK3CGCTSD | |
| SCHEMBL1682739 | 0.71 | — | — | |
| SCHEMBL23457551 | 0.71 | MAPT (0.36) | HTR3AHRH4PDE3BPDE3AHRH3 | |
| SCHEMBL29699548 | 0.71 | MAPT (0.36) | HTR3AHRH4PDE3BPDE3AHRH3 | |
| SCHEMBL22608293 | 0.70 | ENPP2 (0.37) | RXFP1HPGDF7F3ALDH1A1 | |
| SCHEMBL23457507 | 0.68 | HAO1 (0.43) | HPGDSMN1; SMN2ALDH1A1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HTR3A 3268/4885HRH4 2762/4885PDE3B 1379/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HTR3A 3373/4885HRH4 2857/4885PDE3B 1554/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | HTR3A 3268/4885HRH4 2762/4885PDE3B 1379/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HTR3A 3268/4885HRH4 2762/4885PDE3B 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.